2 recruiting, 2 terminated, 1 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow Bladder Squamous Cell Carcinoma: new trials by email Literature Review of Bladder Squamous Cell Carcinoma trials Research Report on Bladder Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-22 |
| Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Carboplatin, Cisplatin, Cystectomy - Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma | Phase 2 | Terminated | Stanford University | 7 | 2019-04-10 | 2023-09-11 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery - Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 21 | 2003-10-01 | 2014-12-23 |
Urinary Bladder Neoplasms (4) · Carcinoma, Renal Cell (2) · Penile Neoplasms (2) · Urachal adenocarcinoma (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Urogenital Neoplasms (2) · Carcinoma, Transitional Cell (1) · Prostatic Neoplasms (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Adenocarcinoma (2) · Carcinoma (2) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Kidney Diseases (2)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · cabozantinib (2) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Cystectomy (1) · Doxorubicin (1) · Gemcitabine (1) · Methotrexate (1) · Vinblastine (1) · durvalumab (1)
National Cancer Institute (NCI) (3) · Emory University (1) · Stanford University (1)
United States (5) · Puerto Rico (1)
Andrea B Apolo (2) · Jacqueline Brown, MD (1) · Robert Weiss (1) · Sandy Srinivas (1)
PMID 35031545, PMID 32915679, PMID 38954785
P30CA072720 (1), P30CA138292 (1), U01CA132194 (1), U10CA180821 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)